Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming tech...
Q1 2026
May 12, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 12, 2025